There was good news and bad news for Zynerba Pharmaceuticals in 2017. First, the good news: The cannabinoid-focused biotech stock is up more than 90% over the last three months. What's the bad news? That gain wasn't enough to offset Zynerba's previous decline. The stock is still down over 20%...
There are three different general types of marijuana stocks on the market. Some are marijuana growers. Others provide supplies to marijuana growers. Then there's the third type of marijuana stock: the biotechs.
Zynerba Pharmaceuticals belongs to the last kind of marijuana stock. Like other...